Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 945 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR ESMO Gastrointestinal Cancers Congress 2024 Munich, Germany, 26-29 June June 14, 2024 When Caregiving Takes a Toll May 28, 2021 Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients... March 17, 2025 Treatment with Tebentafusp Results in Longer Overall Survival Among Previously Untreated... September 27, 2021 Load more HOT NEWS Quitting Smoking Improves Survival in People with Lung Cancer Giving Myself the Most Time and Best Chance at Beating Cancer:... Delivering the future of paediatric brain tumour therapy EMA Recommends Granting a Marketing Authorisation for Vorasidenib
